Neogen Corp (NEOG) Stock Analysis and Metrics

Neogen

NASDAQ: NEOG

$9.40 ▼ -0.21 (-2.24%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.09 Bn

P/E-3.23

P/S2.40

Div. Yield0.00

ROIC (Qtr)-0.34

Total Debt (Qtr)793.30 Mn

Revenue Growth (1y) (Qtr)-4.43

Add ratio to table…

About

Neogen Corporation develops manufactures and markets a diverse line of products and services dedicated to food and animal safety. The company’s mission is to be the leading company in fueling a brighter future for global food safety. Neogen operates worldwide with facilities in the United States Europe Brazil Australia China and Canada. The company exports its products to more than 100 countries through a network of distributors and direct sales teams.

Neogen generates revenue from the sale of diagnostic test kits culture media veterinary instruments pharmaceuticals vaccines diagnostic services genomics testing and software solutions. The Food Safety segment contributes the majority of sales while the Animal Safety segment provides the remainder. In fiscal year 2025 the Food Safety segment accounted for 71.3% of total revenue and the Animal Safety segment accounted for 28.7%. The company also incurs royalty expenses for licensed technology used in certain test kits with rates typically ranging from two to ten percent of sales on those products.

The company operates through the following segments: Food Safety and Animal Safety.

• Food Safety: This segment develops manufactures and markets diagnostic test kits for pathogen toxin allergen detection culture media and related software for food and feed producers processors and regulatory agencies to ensure safety quality and hygiene.

• Animal Safety: This segment develops manufactures and markets veterinary instruments pharmaceuticals vaccines diagnostic products rodent and insect control cleaners disinfectants and genomics testing services for livestock producers veterinarians and companion animal owners worldwide.

Neogen holds a strong position in the food and animal safety markets because of its broad product line and focus on ease of use speed accuracy and customer service. The company competes with many specialized firms and divisions of large multinational corporations but differentiates itself through low cost manufacturing an extensive global distribution network and continuous innovation. Investment in research and development supports the launch of new tests and technologies that keep pace with evolving regulatory and market demands. While no single competitor dominates the entire field Neogen’s combination of product depth and service quality provides a durable advantage.

Neogen serves food and beverage processors meat and poultry producers dairy operations fruit and vegetable growers seafood handlers and bakery manufacturers. In the animal health arena the company sells to veterinary clinics livestock producers pet owners horse farms and research institutions. Government agencies such as the USDA and FDA also use Neogen’s diagnostic tools for monitoring and enforcement. Additionally the company supplies genomics services to breed associations universities and commercial laboratories worldwide.

Investment Thesis

▲ Bull case

Neogen's Food Safety segment demonstrated resilient core growth of 4% despite a challenging macro environment, driven by 11% growth in indicator testing and culture media and strong pathogen test kit performance, indicating underlying demand strength that management did not fully emphasize; this growth trajectory is supported by rising food recalls—FDA recall volume more than doubled year-over-year in 2025—which creates structural tailwinds for Neogen's core offerings as processors increase testing frequency to mitigate brand and financial risks, positioning the company to capture durable, non-cyclical demand even as near-term headwinds like currency fluctuations and freight costs pressure reported results.
The ongoing transition to in-house Petrifilm manufacturing, with 100% of production equipment validated and 17 current SKUs undergoing validation for a November 2026 go-live, represents a hidden catalyst that management underplayed; once operational, in-house production will eliminate dependency on third-party manufacturers, unlock exceptionally high incremental contribution margins on volume growth, and create a near-insurmountable barrier to entry due to the technical complexity and precision required to replicate the Petrifilm platform, enabling sustainable margin expansion and innovation acceleration in custom SKUs for adjacent markets like pharmaceuticals and nutraceuticals—opportunities that were not quantified in guidance but could materially uplift long-term profitability.
The divestiture of the genomics business unit, generating approximately $90 million in fiscal 2025 revenue with mid-teens adjusted EBITDA margins, for $160 million in proceeds (expecting $140 million net in Q2 FY27), is a strategic move that will significantly enhance Neogen's consolidated margin profile by removing a below-average profitability segment; the net proceeds are earmarked for debt reduction, with management anticipating the net debt to adjusted EBITDA ratio to fall below 3x by end of calendar 2026, thereby lowering financial risk and freeing capacity for reinvestment in higher-margin Food Safety initiatives, a balance sheet improvement that was not highlighted as a near-term catalyst despite its tangible impact on leverage and flexibility.
Operational efficiency initiatives, including the advancement of a centralized planning model leveraging AI-enabled supply chain tools and simplification of warehousing, are targeting structural cost reductions beyond temporary headwinds; with 56% of operating expenses tied to salaries and benefits—indicating underinvestment in automation—these efforts are designed to yield sustainable efficiencies that will scale with volume, particularly as Petrifilm production ramps, and are expected to drive significant improvements in free cash flow starting in fiscal 2027, a multi-year transformation benefit that management framed as temporary spend but whose long-term operating leverage was not fully appreciated in current guidance.
The Animal Safety segment's near-term weakness, with core revenue down 8.7% due to supplier disruptions, is poised for a meaningful recovery as U.S. production animal herd sizes near cyclical lows and USDA projects future herd growth aligned with elevated protein demand; this cyclical trough presents a latent inflection point where resolving supplier issues—through strengthened qualification processes and review—could unlock pent-up demand, transforming a current drag into a future growth contributor that the market may be overlooking amid near-term execution challenges.

Neogen's Food Safety segment demonstrated resilient core growth of 4% despite a challenging macro environment, driven by 11% growth in indicator testing and culture media and strong pathogen test kit performance, indicating underlying demand strength that management did not fully emphasize; this growth trajectory is supported by rising food recalls—FDA recall volume more than doubled year-over-year in 2025—which creates structural tailwinds for Neogen's core offerings as processors increase testing frequency to mitigate brand and financial risks, positioning the company to capture durable, non-cyclical demand even as near-term headwinds like currency fluctuations and freight costs pressure reported results.
The ongoing transition to in-house Petrifilm manufacturing, with 100% of production equipment validated and 17 current SKUs undergoing validation for a November 2026 go-live, represents a hidden catalyst that management underplayed; once operational, in-house production will eliminate dependency on third-party manufacturers, unlock exceptionally high incremental contribution margins on volume growth, and create a near-insurmountable barrier to entry due to the technical complexity and precision required to replicate the Petrifilm platform, enabling sustainable margin expansion and innovation acceleration in custom SKUs for adjacent markets like pharmaceuticals and nutraceuticals—opportunities that were not quantified in guidance but could materially uplift long-term profitability.
The divestiture of the genomics business unit, generating approximately $90 million in fiscal 2025 revenue with mid-teens adjusted EBITDA margins, for $160 million in proceeds (expecting $140 million net in Q2 FY27), is a strategic move that will significantly enhance Neogen's consolidated margin profile by removing a below-average profitability segment; the net proceeds are earmarked for debt reduction, with management anticipating the net debt to adjusted EBITDA ratio to fall below 3x by end of calendar 2026, thereby lowering financial risk and freeing capacity for reinvestment in higher-margin Food Safety initiatives, a balance sheet improvement that was not highlighted as a near-term catalyst despite its tangible impact on leverage and flexibility.
Operational efficiency initiatives, including the advancement of a centralized planning model leveraging AI-enabled supply chain tools and simplification of warehousing, are targeting structural cost reductions beyond temporary headwinds; with 56% of operating expenses tied to salaries and benefits—indicating underinvestment in automation—these efforts are designed to yield sustainable efficiencies that will scale with volume, particularly as Petrifilm production ramps, and are expected to drive significant improvements in free cash flow starting in fiscal 2027, a multi-year transformation benefit that management framed as temporary spend but whose long-term operating leverage was not fully appreciated in current guidance.
The Animal Safety segment's near-term weakness, with core revenue down 8.7% due to supplier disruptions, is poised for a meaningful recovery as U.S. production animal herd sizes near cyclical lows and USDA projects future herd growth aligned with elevated protein demand; this cyclical trough presents a latent inflection point where resolving supplier issues—through strengthened qualification processes and review—could unlock pent-up demand, transforming a current drag into a future growth contributor that the market may be overlooking amid near-term execution challenges.

▼ Bear case

Neogen's reported core revenue growth of 0.1% masks a growing divergence between its Food Safety and Animal Safety segments, with Food Safety's 4% core growth being offset by an 8.7% core decline in Animal Safety due to persistent supplier disruptions; management acknowledged these challenges are expected to continue into Q4 as suppliers work through transitions, and the company's reliance on third-party manufacturers for critical inputs—exemplified by the vitamin A shortage and sodium bicarb production issues—reveals a structural vulnerability in its supply chain that short-term fixes like strengthened qualification processes may not adequately resolve, leaving Animal Safety susceptible to recurring volatility that could persistently depress overall revenue growth.
Despite raising full-year revenue guidance to $857–$860 million, Neogen maintained its adjusted EBITDA guidance of $175 million for the fiscal year, implying minimal incremental margin expansion even as revenue increases; this stagnation is driven by multiple lingering headwinds, including freight and transportation cost increases in the high single-digit to low double-digit% range adding approximately $1.5 million per quarter to expenses, the diminishing of prior currency tailwinds due to U.S. dollar strength—which will impact reported growth as 40% of revenue is in non-U.S. dollar currencies—and ongoing sample collection margin pressure from third-party supplier quality issues, all of which management conceded will pressure profitability without a clear path to meaningful operating leverage in the near term.
The Petrifilm manufacturing transition, while positioned as a long-term margin catalyst, remains incomplete and carries execution risk; although 100% of production equipment is validated, only 17 current SKUs are undergoing validation for a November 2026 transition, and any delay in validation or scale-up could postpone the realization of exceptionally high incremental contribution margins, while the company continues to incur duplicative costs during the transition period, with management admitting that transformation-related spending—though excluded from adjusted financials—represents a near-term drag on cash flow that may not decline as quickly as anticipated if operational inefficiencies persist beyond current projections.
Neogen's balance sheet shows $800 million in gross debt (68% fixed rate) with only $159.9 million in cash, resulting in a net debt position that, while expected to improve post-genomics divestiture, remains elevated relative to its adjusted EBITDA generation; the company anticipates the net debt to adjusted EBITDA ratio will fall below 3x by end of calendar 2026, but this assumes successful execution of the divestiture in Q2 FY27 and continued free cash flow improvement, both of which are contingent on resolving Animal Safety supplier issues and avoiding further macroeconomic disruptions—such as prolonged geopolitical tensions affecting logistics costs—that could delay deleveraging and keep financial risk elevated longer than market expectations.
The company's increased investment in innovation, including the fourth-quarter research-scale R&D line at the Minnesota facility for custom Petrifilm SKUs, signals a strategic shift but carries uncertain returns; while management highlighted the potential to expand into pharmaceuticals, cosmetics, and nutraceuticals, no concrete timelines, revenue projections, or margin expectations were provided for these adjacent market opportunities, leaving investors to rely on faith in unproven innovation rather than near-term fundamentals, especially as Food Safety core growth remains tied to low single-digit market growth rates and the broader industry faces ongoing volatility from feed costs, factory consolidations, and geopolitical factors like the Iran conflict that could suppress customer spending on testing solutions despite rising recall rates.

Neogen's reported core revenue growth of 0.1% masks a growing divergence between its Food Safety and Animal Safety segments, with Food Safety's 4% core growth being offset by an 8.7% core decline in Animal Safety due to persistent supplier disruptions; management acknowledged these challenges are expected to continue into Q4 as suppliers work through transitions, and the company's reliance on third-party manufacturers for critical inputs—exemplified by the vitamin A shortage and sodium bicarb production issues—reveals a structural vulnerability in its supply chain that short-term fixes like strengthened qualification processes may not adequately resolve, leaving Animal Safety susceptible to recurring volatility that could persistently depress overall revenue growth.
Despite raising full-year revenue guidance to $857–$860 million, Neogen maintained its adjusted EBITDA guidance of $175 million for the fiscal year, implying minimal incremental margin expansion even as revenue increases; this stagnation is driven by multiple lingering headwinds, including freight and transportation cost increases in the high single-digit to low double-digit% range adding approximately $1.5 million per quarter to expenses, the diminishing of prior currency tailwinds due to U.S. dollar strength—which will impact reported growth as 40% of revenue is in non-U.S. dollar currencies—and ongoing sample collection margin pressure from third-party supplier quality issues, all of which management conceded will pressure profitability without a clear path to meaningful operating leverage in the near term.
The Petrifilm manufacturing transition, while positioned as a long-term margin catalyst, remains incomplete and carries execution risk; although 100% of production equipment is validated, only 17 current SKUs are undergoing validation for a November 2026 transition, and any delay in validation or scale-up could postpone the realization of exceptionally high incremental contribution margins, while the company continues to incur duplicative costs during the transition period, with management admitting that transformation-related spending—though excluded from adjusted financials—represents a near-term drag on cash flow that may not decline as quickly as anticipated if operational inefficiencies persist beyond current projections.
Neogen's balance sheet shows $800 million in gross debt (68% fixed rate) with only $159.9 million in cash, resulting in a net debt position that, while expected to improve post-genomics divestiture, remains elevated relative to its adjusted EBITDA generation; the company anticipates the net debt to adjusted EBITDA ratio will fall below 3x by end of calendar 2026, but this assumes successful execution of the divestiture in Q2 FY27 and continued free cash flow improvement, both of which are contingent on resolving Animal Safety supplier issues and avoiding further macroeconomic disruptions—such as prolonged geopolitical tensions affecting logistics costs—that could delay deleveraging and keep financial risk elevated longer than market expectations.
The company's increased investment in innovation, including the fourth-quarter research-scale R&D line at the Minnesota facility for custom Petrifilm SKUs, signals a strategic shift but carries uncertain returns; while management highlighted the potential to expand into pharmaceuticals, cosmetics, and nutraceuticals, no concrete timelines, revenue projections, or margin expectations were provided for these adjacent market opportunities, leaving investors to rely on faith in unproven innovation rather than near-term fundamentals, especially as Food Safety core growth remains tied to low single-digit market growth rates and the broader industry faces ongoing volatility from feed costs, factory consolidations, and geopolitical factors like the Iran conflict that could suppress customer spending on testing solutions despite rising recall rates.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password